Evidence map›Paper›PMID 34423389›Full record

ArticleInflammation2021

Paeoniflorin Suppresses Rheumatoid Arthritis Development via Modulating the Circ-FAM120A/miR-671-5p/MDM4 Axis.

Junfu Ma, Qingliang Meng, Junping Zhan, Huilian Wang, Wei Fan, Yanqi Wang, Sudan Zhang, Hua Bian, Fuzeng Zheng

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Role of ceRNA network in inflammatory cells of rheumatoid arthritis.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. Drug Candidates for Autoimmune Diseases.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Junfu Ma *Department of Rheumatology, Henan Province Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine), Henan University of Traditional Chinese Medicine, Henan Province, Zhengzhou City, China.
Qingliang Meng *Department of Rheumatology, Henan Province Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine), Henan University of Traditional Chinese Medicine, Henan Province, Zhengzhou City, China.
Junping ZhanDepartment of Rheumatology, Henan Province Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine), Henan University of Traditional Chinese Medicine, Henan Province, Zhengzhou City, China.
Huilian WangDepartment of Rheumatology, Henan Province Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine), Henan University of Traditional Chinese Medicine, Henan Province, Zhengzhou City, China.
Wei FanDepartment of Rheumatology, Henan Province Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine), Henan University of Traditional Chinese Medicine, Henan Province, Zhengzhou City, China.
Yanqi WangHenan Province Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine), Henan University of Traditional Chinese Medicine, Henan Province, Zhengzhou City, China.
Sudan ZhangHenan Province Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine), Henan University of Traditional Chinese Medicine, Henan Province, Zhengzhou City, China.
Hua BianZhang Zhongjing College of Chinese Medicine, Nanyang Institute of Technology, Henan Province, Nanyang City, China.
Fuzeng ZhengDepartment of Rheumatology, Henan Province Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine), Henan University of Traditional Chinese Medicine, Henan Province, Zhengzhou City, China. zhengfuzeng123@126.com.ORCID http://orcid.org/0000-0002-9746-2134
Henan University of Traditional Chinese Medicine · CNNanyang Institute of Technology · CN

Funding

Key subject of Henan Province Traditional Chinese Medicine scientific research project No.2018ZY1011National Natural Science Foundation of China Youth Project No.81804050
6 · The paper itself

Abstract

Paeoniflorin is an active ingredient derived from Paeonia, which has an anti-inflammatory effect. However, the potential role and basis of paeoniflorin in rheumatoid arthritis (RA) are indistinct. Cell viability, cycle distribution, migration, and invasion were evaluated via Cell Counting Kit-8 (CCK-8), flow cytometry, and transwell assays. The contents of inflammatory cytokines were examined using enzyme-linked immunosorbent assay (ELISA). RNA expression levels were determined via qRT-PCR and western blot. The targeting relationship between miR-671-5p and circ-FAM120A (hsa_circ_0003972) or murine double minute 4 (MDM4) was validated via dual-luciferase reporter assay. Paeoniflorin restrained proliferation, migration, invasion, and inflammation and accelerated cell cycle arrest in RA fibroblast-like synoviocytes (RA-FLSs). Circ-FAM120A was boosted in RA synovial tissues and RA-FLSs. Circ-FAM120A upregulation, miR-671-5p knockdown, or MDM4 augmentation reversed the repressive effect of paeoniflorin on RA-FLS progression. Moreover, paeoniflorin attenuated RA-FLS progression by regulating the circ-FAM120A/miR-671-5p/MDM4 axis. Paeoniflorin inhibited RA-FLS proliferation, mobility, and inflammation and triggered cell cycle arrest via mediating the circ-FAM120A/miR-671-5p/MDM4 pathway.

Indexed as

Anti-Inflammatory AgentsAntirheumatic AgentsArthritis, RheumatoidCase-Control StudiesCell Cycle CheckpointsCell Cycle ProteinsCell MovementCell ProliferationCells, CulturedCytokinesFibroblastsGlucosidesGlycosidesHumansInflammation MediatorsMicroRNAsAnti-Inflammatory AgentsAntirheumatic AgentsCell Cycle ProteinsCytokinesGlucosidesGlycosidesInflammation MediatorsMDM4 protein, humanMicroRNAsMIRN671 microRNA, humanMonoterpenespeoniflorinProto-Oncogene ProteinsRNA, CircularCirc-FAM120AmDM4miR-671-5pPaeoniflorinRheumatoid arthritis

Identifiers

PMID34423389
OpenAlexW3194668410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.